Nahdi Medical Company

4164.SRSAUHealthcare● Active

$95.40

$-0.10(-0.10%)

Market Cap$12.4B

P/E Ratio—

52W High$132.1

52W Low$91

Avg Volume138K

Open$95.95

Beta0.12

Overview

Nahdi Medical Company (4164.SR) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

4164.SR · free cash flow · updated Jun 15, 2026

Core FCF metrics

4164.SR · FCF · TTM · margin & CAGR

Free cash flow was $806.8M for FY2025 (fiscal year ending 2025-12-31), down 27.1% year-over-year The FCF margin was 7.9%. Five-year CAGR stands at -8.6%.

FY2025 Free Cash Flow$806.8M▼ -27.1% YoY

Trailing 12M (TTM)$1.02Btrailing 4 quarters sum

FCF Margin7.9%$806.8M ÷ revenue

3-Year CAGR-16.6%FY2022 → FY2025

5-Year CAGR-8.6%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

4164.SR · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$1.19B(387M)$806.8M▼ 27.1%7.9%

FY2024$1.49B(384M)$1.11B▲ +12.5%11.7%

FY2023$1.37B(385M)$984.2M▼ 29.3%11.3%

FY2022$1.67B(275M)$1.39B▲ +35.5%16.2%

FY2021$1.33B(306M)$1.03B▼ 18.8%12.7%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

4164.SR · P/FCF · FCF yield · FCF per share

Nahdi Medical Company (4164.SR) trades at a FCF yield of 8.19% and a price-to-free-cash-flow ratio of 12.2x. FCF per share stands at $7.81, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

8.19%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$7.81

TTM FCF ÷ Shares Outstanding

Price / FCF

x12.2

Share Price ÷ FCF per Share

EV / FCF (TTM)

x12.9

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

4164.SR · cash flow statement · operating / investing / financing

For FY2025, Nahdi Medical Company generated $1.19B in operating cash flow and spent 387M in capital expenditures, yielding $806.8M in free cash flow.

Operating Activities

+$1.19B

Cash from core business operations

2025-12-31

Investing Activities

−$414.5M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$1.18B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($1.19B) − |CapEx| (387M) = FCF ($806.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

4164.SR vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Nahdi Medical CompanyYOU

4164.SR

$806.8M-27.1%7.9%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Nahdi Medical Company (4164.SR) reported free cash flow of $806.8M for FY2025 (fiscal year ending 2025-12-31), down 27.1% year-over-year. The FCF margin was 7.9%.

Based on available data, Nahdi Medical Company has maintained positive free cash flow for at least 9 fiscal year(s). FCF peaked at $1.39B in FY2022. The 5-year CAGR stands at -8.6%.

Nahdi Medical Company's FCF yield is 8.19% and price-to-FCF ratio is 12.2x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

4164.SR free cash flow · 8 questions

Nahdi Medical Company free cash flow was $806.8M for FY2025, down 27.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $1.02B.

4164.SR free cash flow4164.SR FCF4164.SR FCF 20254164.SR free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Nahdi Medical Company · Nahdi Medical Company SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026